Overview

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).
Phase:
Phase 2
Details
Lead Sponsor:
The Dana Foundation
Treatments:
Selegiline
Thioctic Acid